ASH 2024 | MagnetisMM-3: update on efficacy and safety of less frequent dosing of elranatamab in R/R myeloma

So elranatumab is a BCMA/CD3 bispecific and MagnetisMM3 is a Phase II registrational study that was designed for patients with triple refractory multiple myeloma, so individuals that had received and been refractory to at least one proteasome inhibitor, one IMiD, or one anti-CD38 monoclonal antibody. 123 patients were enrolled, and the follow-up for these patients has been sequentially updated and presented. The overall response rate in this study is around 60%. This is, of course, in a triple refractory patient population, and also the majority of which were penta refractory as well. 

In the current updated presentation, the data from every four week, or transition to every four week administration is the focus. Patients received elranatumab once a week for the first six months of treatment, then transitioned if they were in PR, or better, to every other week for an additional six months, and then, or until the study was sort of modified to then allow for a transition to every four week therapy. The data is evaluating continued response among individuals that were able to transition to every four weeks, as well as side effects for the six months prior to transition, and as well as six months post-transition. And the overall findings were that the numerical incidents of adverse events, specifically infections, and other side effects like GI side effects and fatigue diminished. However, efficacy was not affected by the transition to every four-week therapy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.